B K Bhuyan
Overview
Explore the profile of B K Bhuyan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopes N, Miller H, Young N, Bhuyan B
Cancer Chemother Pharmacol
. 1997 Jan;
41(1):37-47.
PMID: 9443612
Paclitaxel (Taxol) a clinically active anticancer agent, exerts its cytotoxicity by inducing tubulin polymerization, leading to cellular mitotic block. In contrast, other antimitotic drugs, such as colchicine, podophyllotoxin, and vinblastine,...
2.
Smith K, Folz B, Adams E, Bhuyan B
Cancer Chemother Pharmacol
. 1995 Jan;
35(6):471-82.
PMID: 7533669
Adozelesin is a highly potent alkylating agent that undergoes binding in the minor groove of double-stranded DNA (ds-DNA) at A-T-rich sequences followed by covalent bonding with N-3 of adenine in...
3.
Butryn R, Smith K, Adams E, Abraham I, Stackpole J, Sampson K, et al.
Cancer Chemother Pharmacol
. 1994 Jan;
34(1):44-50.
PMID: 7513620
Bizelesin (U-77779) is a highly potent bis-alkylating antitumor agent that is effective against several tumor systems in vitro and in vivo. V79 cells that were 125- to 250-fold resistant to...
4.
Bhuyan B, Smith K, Kelly R, Adams E, Abraham I, Sampson K
Cancer Res
. 1993 Mar;
53(6):1354-9.
PMID: 8443816
Adozelesin is a highly potent alkylating agent which has entered clinical trials based on its unique mechanisms of action and broad-spectrum antitumor activity in vivo. V79 cells resistant to adozelesin...
5.
Lopes N, Adams E, Pitts T, Bhuyan B
Cancer Chemother Pharmacol
. 1993 Jan;
32(3):235-42.
PMID: 8098996
Taxol is a clinically active anticancer drug, which exerts its cytotoxicity by the unique mechanism of polymerizing tubulin monomers into microtubules and stabilizing microtubules. Our studies with ovarian (hamster CHO...
6.
Bhuyan B, Smith K, Adams E, Petzold G, McGovren J
Cancer Res
. 1992 Oct;
52(20):5687-92.
PMID: 1394193
Adozelesin (U-73975) is an extremely potent cytotoxic agent which causes 90% lethality, after 2 h exposure in vitro, of Chinese hamster ovary and lung (CHO and V79), mouse melanoma (B16),...
7.
Bhuyan B, Smith K, Adams E, Wallace T, Von Hoff D, Li L
Cancer Chemother Pharmacol
. 1992 Jan;
30(5):348-54.
PMID: 1505072
Adozelesin (U-73975) was highly cytotoxic to V79 cells in culture and was more cytotoxic than several clinically active antitumor drugs as determined in a human tumor-cloning assay. Phase-specificity studies showed...
8.
Bhuyan B, Folz S, DeZwaan J, Northcott S, Alberts D, Garcia D, et al.
Cancer Commun
. 1991 Feb;
3(2):53-9.
PMID: 1995028
The cytotoxicity of tetraplatin (dl-trans), its d- and l-isomers, and cisplatin for four human tumor cell lines (myeloma 8226, ovarian 2008, A2780, and OVCAR-3), their cisplatin-resistant variants, and three rodent...
9.
Badiner G, Moy B, Smith K, Tarpley W, Groppi V, Bhuyan B
Br J Cancer
. 1990 Sep;
62(3):378-84.
PMID: 2145026
Menogaril is an anthracycline presently in Phase II clinical trials. Menogaril-resistant mouse leukaemia P388 cells were developed in vitro by 4 months of exposure to step-wise increasing concentrations of menogaril...
10.
Satpathy R, Bhuyan B, Das D, Pant K, Sarangi J, Pani S
J Indian Med Assoc
. 1990 Jun;
88(6):168-9.
PMID: 2230164
No abstract available.